# Kimia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kimia-therapeutics

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.kimiatx.com
- Total disclosed funding: $60M
- Latest round: Series A (Aug 9, 2023)
- Investors on record: 3

## About

Based in California, US, and founded in 2023, Kimia Therapeutics Inc operates as a biotechnology research company that offers a biotechnology platform that develops chemical atlas for the treatment of human diseases. In December 2023, Kimia Therapeutics, Inc. raised USD 55 million in series A funding led by Dimension Management, The Column Group, and Horizons Ventures. The company was Co-founded by its CEO and president Stig K. Hansen, Jack Sadowsky, and Ray Fucini.

The company offers generative chemistry which is based on successive iterations of chemical design using synthesis, chemical biology, and machine learning. The firm provides deeper insights from empirical data for the development of medicines.

The company plans to use the December 2023 funding to boost research and development efforts and enhance the company's partnership with Carmot Therapeutics Inc. for metabolic programs.

## Funding rounds

- Series A, Aug 9, 2023, $60M — The Column Group, Horizons Ventures, Dimension Management

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A
- Horizons Ventures — Series A
- Dimension Management (https://capitalatlas.ai/funds/dimension-management) — Series A